United Kingdom· GB-APID-23495011000001109
Lojuxta 10mg capsules
A lomitapide product containing lomitapide, registered in United Kingdom by Chiesi Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lomitapide is registered in 14 of 19 countries.
Countries holding a registration under ATC C10AX12 (lomitapide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Lomitapide · ATC C10AX12
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lomitapide
- Manufacturer
- Chiesi Ltd
- Country
- United Kingdom (GB)
- ATC code
- C10AX12
- ATC class
- Lomitapide
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 7
- gtin5060345160017
- gtin05397203001015
- gtin5397203001367
- gtin05397203001374
- gtin5397203001374
- gtin5028613003619
- gtin05028613003619
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
299 interactions on record for lomitapide.
Graded by severity as the source publishes them — 206 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lomitapide · interactions on record
299 records
- 206 severe
- 86 moderate
- 7 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- AprepitantA04AD12severe
- Chenodeoxycholic acidA05AA01severe
- SulfasalazineA07EC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lomitapide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesJuxtapidAmryt Pharmaceuticals DAC
- CanadaJUXTAPIDCHIESI FARMACEUTICI S.P.A.
- CzechiaLOJUXTAChiesi Farmaceutici S.p.A., Parma
- SpainLOJUXTA 10 MG CAPSULAS DURASChiesi Farmaceutici S.P.A.
- FinlandLojuxtaChiesi Farmaceutici S.p.A.
- FranceLOJUXTA 10 mg, gélulesCHIESI FARMACEUTICI
- BelgiumLojuxta 10 mgChiesi Farmaceutici
- IcelandLojuxtaChiesi Farmaceutici S.p.A.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lojuxta
- Liechtenstein · Lojuxta
- Norway · Lojuxta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/76ce93c7-cb3c-4de6-bdc3-f20d555bb03a GET /v1/drugs/76ce93c7-cb3c-4de6-bdc3-f20d555bb03a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "23495011000001109",
"desc": "Lojuxta 10mg capsules (Chiesi Ltd)",
"form": "Oral capsule",
"vpid": "23604411000001100",
"source": "dmd",
"vtm_id": "864004002",
"strength": "10 mg",
"substance": "Lomitapide",
"ingredient": "Lomitapide mesylate",
"supplier_code": "9052511000001105"
}See everything about lomitapide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.